Project Grant R01AR084468
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant of $413,655 on August 1, 2025 to Arizona State University (ASU) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop biomaterials with temporal control of proteins, such as Bone Morphogenetic Proteins (BMPs), to enhance bone repair. The research aims to mimic natural extracellular matrix interactions and synergies...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $676,841 Project Grant titled "LEVERAGING HUMAN MUSCULOSKELETAL DEVELOPMENT TO IDENTIFY CAUSAL DISEASE VARIANTS" to President and Fellows of Harvard College. The award period runs from August 1, 2025 to July 31, 2030 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The objective of the project is to conduct targeted functional genomic studies...
- The federal Project Grant award R56AR082872 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $395,171 award to Rush University Medical Center aims to determine the in vivo chemical changes of contemporary ultra-high molecular weight polyethylene (PE) tibial liners used in total knee arthroplasty (TKA) procedures, and how these changes impact wear behavior...
- The University of Southern California (USC) received a $628,174 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The purpose of this multi-year grant, with an ultimate completion date of March 31, 2030, is to support research into the cellular origins and molecular mechanisms underlying the development of arthrofibrosis, a debilitating...
- This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- The federal Project Grant award of $649,391 provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting research to enhance healing after injury. The overarching objective is to define the mechanisms that restrain tissue regeneration in order to develop new therapeutics to improve healing of the gut and skin following injury or infection. The 5-year project, which...
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $529,616 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Brigham & Women's Hospital Inc. to conduct research on the role of Notch signaling and fibrosis in treatment-resistant rheumatoid arthritis. The project aims to define the molecular mechanisms by which Notch signaling regulates transforming growth factor beta (TGF-β) signaling in...
- This $663,901 Project Grant was awarded on September 1, 2025 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant supports Emory University's research to understand how the gut microbiome and T-cells influence fracture healing. The project aims to investigate how gut bacteria and immune cells, particularly Th17 cells, can be leveraged to improve fracture repair and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $439,791 Project Grant to The University of Texas Southwestern Medical Center on March 1, 2025 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports research to investigate the molecular mechanisms of myoblast fusion, which is essential for skeletal muscle development and regeneration. The research aims to understand the cellular and...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $596,189 project grant to Rush University Medical Center in Chicago, Illinois under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant aims to develop comprehensive preclinical testing strategies and further elucidate the factors contributing to in vivo fretting-corrosion damage and adverse local tissue reactions within modular junctions of total joint replacements. The central hypothesis is that the onset and progression of fretting-corrosion and adverse local tissue reactions are dependent on macro- and micro-surface geometry, manufacturing tolerances, and alloy microstructure, and can be pre-clinically predicted through multi-scale finite element analysis, partial-slip fretting and corrosion tests under cell-accelerated corrosion conditions, and alloy microstructure characterization. The project period runs from Sep 5, 2025 to Jul 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/19/25 | ||
| Not listed | $596.2k | 9/5/25 |